Capstone Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Capstone Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$799K	Sell	24,044 -2,575	-10%	-$79.7K	0.02%	666
2017 Q1	$854K	Sell	26,619 -687	-3%	-$23.4K	0.02%	640
2016 Q4	$990K	Sell	27,306 -1,260	-4%	-$50.3K	0.03%	585
2016 Q3	$1.31M	Sell	28,566 -100	-0.3%	-$5.22K	0.04%	519
2016 Q2	$1.44M	Hold	28,666	–	–	0.04%	473
2016 Q1	$1.53M	Hold	28,666	–	–	0.04%	476
2015 Q4	$1.88M	Hold	28,666	–	–	0.05%	413
2015 Q3	$1.62M	Hold	28,666	–	–	0.05%	425
2015 Q2	$1.69M	Hold	28,666	–	–	0.05%	427
2015 Q1	$1.79M	Sell	28,666 -303	-1%	-$17.6K	0.05%	431
2014 Q4	$1.67M	Sell	28,969 -497	-2%	-$27.7K	0.05%	437
2014 Q3	$1.58M	Sell	29,466 -18,525	-39%	-$981K	0.05%	395
2014 Q2	$2.52M	Buy	47,991 +224	+0.5%	+$11.4K	0.08%	283
2014 Q1	$2.52M	Buy	47,767 +1,011	+2%	+$46.7K	0.08%	302
2013 Q4	$1.87M	Buy	46,756 +182	+0.4%	+$7.17K	0.05%	396
2013 Q3	$1.76M	Hold	46,574	–	–	0.04%	512
2013 Q2	$1.83M	Buy	+46,574	New	+$1.81M	0.05%	447

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capstone Asset Management's TEVA Position: Q2 2017 in Review

Capstone Asset Management reduced its Teva Pharmaceuticals (TEVA) stake by 9.7% in Q2 2017, selling an estimated $79.7K and leaving 24,044 shares worth $799K. The position accounts for 0.02% of the portfolio, ranked #666.

Capstone Asset Management first reported a position in TEVA in Q2 2013 and has held it in 17 quarters since. The position peaked at $2.52M in Q1 2014. 648 funds tracked by Wall St. Rank hold TEVA as of Q2 2017.

Capstone Asset Management held 24,044 shares of Teva Pharmaceuticals worth $799K as of Q2 2017.
Capstone Asset Management sold 2,575 Teva Pharmaceuticals shares in Q2 2017, an estimated $79.7K.
Teva Pharmaceuticals made up 0.02% of Capstone Asset Management's portfolio in Q2 2017, its #666 holding.
Capstone Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
Capstone Asset Management's Teva Pharmaceuticals position peaked at $2.52M in Q1 2014.
648 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.